• Explore /
  • Poster
  • / A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non–small-cell lung cancer (NSCLC).

A phase 1 first-in-human study of interferon beta (IFNβ) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non–small-cell lung cancer (NSCLC).

Abstract Poster

Authors

null

Andreas Nicholas Saltos

Moffitt Cancer Center, Tampa, FL

Andreas Nicholas Saltos , Christy Arrowood , Georgia Beasley , James Ronald , Ghassan El-Haddad , Luiziane Guerra-Guevara , Uzma Khan , Steven Wolf , Lin Gu , Xiaofei F. Wang , Dana Foresman , Xiaoqing Yu , Mark J. Cantwell , Scott Joseph Antonia , Amer A Beg , Neal E. Ready

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT05076760

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2569)

DOI

10.1200/JCO.2023.41.16_suppl.2569

Abstract #

2569

Poster Bd #

411

Abstract Disclosures

Similar Posters

First Author: Raffit Hassan

First Author: Andreas Nicholas Saltos

First Author: Michael Bitzer

First Author: Amin Nassar